Patent · US Active

Immunogenic product comprising IL-4 and/or IL-13 for treating disorders associated with aberrant IL-4 and/or IL 13 expression or activity

US12059457B2 · kind B2 · utility

0Cited by

4References

8Claims

0Family size

Assignees

NEOVACS · FR
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
INSTITUT PASTEUR · FR

Inventors

Géraldine GROUARD-VOGEL · Paris, FR
Eva CONDE GARCÌA · Paris, FR
Romain BERTRAND · Paris, FR
Noémie CAILLOT · Paris, FR
Laurent REBER · Antony, FR
Pierre BRUHNS · Paris, FR
Vincent Serra · Bondoufle, FR

Key dates

Filing date	May 29, 2019
Grant date	Aug 13, 2024
Priority date	—
Expiry date	May 29, 2039

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/6081
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

An immunogenic product including a cytokine conjugated with a carrier protein, wherein the cytokine is selected from the group including IL-4, IL-13 and mixtures thereof, and wherein the carrier protein is CRM197. Further, a method for manufacturing the immunogenic product. Also, the therapeutic use of the immunogenic product for treating an inflammatory disorder associated with aberrant IL-4 and/or IL-13 expression or activity.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.